Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)

Completed

• Conditions: Rosacea

• Registration Number: NCT02637232
• Lead Sponsor: Galderma R&D

Brief Summary

The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-10
• Study First Submitted: 2015-12-16
• Study First Submitted QC: 2015-12-21
• Study First Posted: 2015-12-22
• Primary Completion: 2016-05
• Study Completion: 2016-05
• Results First Submitted: 2018-02-15
• Status Verified: 2021-05
• Results First Submitted QC: 2021-05-06
• Last Update Submitted: 2021-05-06
• Results First Posted: 2021-05-28
• Last Update Posted: 2021-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 301

Inclusion Criteria

• Patients to whom the physician has already decided to prescribe Mirvaso® /OnrelteaTM according to package insert

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Satisfaction Among Patients to Whom Mirvaso®/OnrelteaTM is Prescribed Question	Week 4

Trial Locations

Locations (1)

Investigator site 1; 🇨🇦 Hamilton, Canada